nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Temozolomide—melanoma	0.174	0.576	CbGbCtD
Maraviroc—CYP3A4—Vemurafenib—melanoma	0.0951	0.316	CbGbCtD
Maraviroc—CYP3A4—Docetaxel—melanoma	0.0326	0.108	CbGbCtD
Maraviroc—Alanine aminotransferase increased—Temozolomide—melanoma	0.000814	0.00216	CcSEcCtD
Maraviroc—Colitis—Docetaxel—melanoma	0.000812	0.00216	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000809	0.00215	CcSEcCtD
Maraviroc—Abdominal distension—Temozolomide—melanoma	0.000803	0.00213	CcSEcCtD
Maraviroc—Pneumonia—Dactinomycin—melanoma	0.000791	0.0021	CcSEcCtD
Maraviroc—Pancytopenia—Carmustine—melanoma	0.000784	0.00208	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00078	0.00207	CcSEcCtD
Maraviroc—Neutropenia—Carmustine—melanoma	0.000772	0.00205	CcSEcCtD
Maraviroc—Decreased appetite—Vemurafenib—melanoma	0.000772	0.00205	CcSEcCtD
Maraviroc—Bronchitis—Temozolomide—melanoma	0.000767	0.00204	CcSEcCtD
Maraviroc—Stomatitis—Dactinomycin—melanoma	0.000767	0.00204	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Vemurafenib—melanoma	0.000767	0.00204	CcSEcCtD
Maraviroc—Fatigue—Vemurafenib—melanoma	0.000766	0.00203	CcSEcCtD
Maraviroc—Neoplasm—Docetaxel—melanoma	0.000765	0.00203	CcSEcCtD
Maraviroc—Constipation—Vemurafenib—melanoma	0.000759	0.00202	CcSEcCtD
Maraviroc—Pancytopenia—Temozolomide—melanoma	0.000758	0.00201	CcSEcCtD
Maraviroc—Neutropenia—Temozolomide—melanoma	0.000746	0.00198	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Temozolomide—melanoma	0.000742	0.00197	CcSEcCtD
Maraviroc—Pneumonia—Carmustine—melanoma	0.000741	0.00197	CcSEcCtD
Maraviroc—Depression—Carmustine—melanoma	0.000734	0.00195	CcSEcCtD
Maraviroc—Agranulocytosis—Dactinomycin—melanoma	0.000734	0.00195	CcSEcCtD
Maraviroc—Renal failure—Carmustine—melanoma	0.000724	0.00192	CcSEcCtD
Maraviroc—Neuropathy peripheral—Carmustine—melanoma	0.000722	0.00192	CcSEcCtD
Maraviroc—Stomatitis—Carmustine—melanoma	0.000718	0.00191	CcSEcCtD
Maraviroc—Pneumonia—Temozolomide—melanoma	0.000716	0.0019	CcSEcCtD
Maraviroc—Infestation—Temozolomide—melanoma	0.000711	0.00189	CcSEcCtD
Maraviroc—Infestation NOS—Temozolomide—melanoma	0.000711	0.00189	CcSEcCtD
Maraviroc—Depression—Temozolomide—melanoma	0.000709	0.00189	CcSEcCtD
Maraviroc—Blood alkaline phosphatase increased—Docetaxel—melanoma	0.000706	0.00188	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000705	0.00187	CcSEcCtD
Maraviroc—Body temperature increased—Vemurafenib—melanoma	0.000702	0.00187	CcSEcCtD
Maraviroc—Pharyngitis—Dactinomycin—melanoma	0.000701	0.00186	CcSEcCtD
Maraviroc—Neuropathy peripheral—Temozolomide—melanoma	0.000697	0.00185	CcSEcCtD
Maraviroc—Stomatitis—Temozolomide—melanoma	0.000694	0.00184	CcSEcCtD
Maraviroc—Deafness—Docetaxel—melanoma	0.000686	0.00182	CcSEcCtD
Maraviroc—Hepatic failure—Docetaxel—melanoma	0.000683	0.00182	CcSEcCtD
Maraviroc—Hepatobiliary disease—Temozolomide—melanoma	0.000673	0.00179	CcSEcCtD
Maraviroc—Alopecia—Bleomycin—melanoma	0.000669	0.00178	CcSEcCtD
Maraviroc—Erythema multiforme—Dactinomycin—melanoma	0.000668	0.00177	CcSEcCtD
Maraviroc—Sinusitis—Temozolomide—melanoma	0.000668	0.00177	CcSEcCtD
Maraviroc—Erythema—Bleomycin—melanoma	0.000659	0.00175	CcSEcCtD
Maraviroc—Hallucination—Carmustine—melanoma	0.000658	0.00175	CcSEcCtD
Maraviroc—Hypersensitivity—Vemurafenib—melanoma	0.000654	0.00174	CcSEcCtD
Maraviroc—Connective tissue disorder—Carmustine—melanoma	0.000649	0.00173	CcSEcCtD
Maraviroc—Asthenia—Vemurafenib—melanoma	0.000637	0.00169	CcSEcCtD
Maraviroc—Hallucination—Temozolomide—melanoma	0.000636	0.00169	CcSEcCtD
Maraviroc—Pharyngitis—Temozolomide—melanoma	0.000634	0.00168	CcSEcCtD
Maraviroc—Urinary tract disorder—Temozolomide—melanoma	0.000631	0.00168	CcSEcCtD
Maraviroc—Pruritus—Vemurafenib—melanoma	0.000628	0.00167	CcSEcCtD
Maraviroc—Connective tissue disorder—Temozolomide—melanoma	0.000628	0.00167	CcSEcCtD
Maraviroc—Urethral disorder—Temozolomide—melanoma	0.000626	0.00166	CcSEcCtD
Maraviroc—Alopecia—Dactinomycin—melanoma	0.000624	0.00166	CcSEcCtD
Maraviroc—Eye disorder—Carmustine—melanoma	0.000618	0.00164	CcSEcCtD
Maraviroc—Erythema—Dactinomycin—melanoma	0.000615	0.00163	CcSEcCtD
Maraviroc—Anaemia—Bleomycin—melanoma	0.000609	0.00162	CcSEcCtD
Maraviroc—Diarrhoea—Vemurafenib—melanoma	0.000608	0.00161	CcSEcCtD
Maraviroc—Erythema multiforme—Temozolomide—melanoma	0.000604	0.0016	CcSEcCtD
Maraviroc—Eye disorder—Temozolomide—melanoma	0.000597	0.00159	CcSEcCtD
Maraviroc—Cardiac disorder—Temozolomide—melanoma	0.000593	0.00158	CcSEcCtD
Maraviroc—Leukopenia—Bleomycin—melanoma	0.00059	0.00157	CcSEcCtD
Maraviroc—Dizziness—Vemurafenib—melanoma	0.000587	0.00156	CcSEcCtD
Maraviroc—Alopecia—Carmustine—melanoma	0.000584	0.00155	CcSEcCtD
Maraviroc—Angiopathy—Temozolomide—melanoma	0.000579	0.00154	CcSEcCtD
Maraviroc—Mental disorder—Carmustine—melanoma	0.000579	0.00154	CcSEcCtD
Maraviroc—Mediastinal disorder—Temozolomide—melanoma	0.000576	0.00153	CcSEcCtD
Maraviroc—Erythema—Carmustine—melanoma	0.000575	0.00153	CcSEcCtD
Maraviroc—Malnutrition—Carmustine—melanoma	0.000575	0.00153	CcSEcCtD
Maraviroc—Cough—Bleomycin—melanoma	0.000575	0.00153	CcSEcCtD
Maraviroc—Anaemia—Dactinomycin—melanoma	0.000568	0.00151	CcSEcCtD
Maraviroc—Vomiting—Vemurafenib—melanoma	0.000565	0.0015	CcSEcCtD
Maraviroc—Alopecia—Temozolomide—melanoma	0.000564	0.0015	CcSEcCtD
Maraviroc—Myalgia—Bleomycin—melanoma	0.000561	0.00149	CcSEcCtD
Maraviroc—Abdominal pain upper—Docetaxel—melanoma	0.000561	0.00149	CcSEcCtD
Maraviroc—Orthostatic hypotension—Docetaxel—melanoma	0.000561	0.00149	CcSEcCtD
Maraviroc—Rash—Vemurafenib—melanoma	0.00056	0.00149	CcSEcCtD
Maraviroc—Mental disorder—Temozolomide—melanoma	0.00056	0.00149	CcSEcCtD
Maraviroc—Dermatitis—Vemurafenib—melanoma	0.000559	0.00149	CcSEcCtD
Maraviroc—Headache—Vemurafenib—melanoma	0.000556	0.00148	CcSEcCtD
Maraviroc—Erythema—Temozolomide—melanoma	0.000556	0.00148	CcSEcCtD
Maraviroc—Malnutrition—Temozolomide—melanoma	0.000556	0.00148	CcSEcCtD
Maraviroc—Breast disorder—Docetaxel—melanoma	0.000555	0.00147	CcSEcCtD
Maraviroc—Discomfort—Bleomycin—melanoma	0.000554	0.00147	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000553	0.00147	CcSEcCtD
Maraviroc—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000553	0.00147	CcSEcCtD
Maraviroc—Leukopenia—Dactinomycin—melanoma	0.00055	0.00146	CcSEcCtD
Maraviroc—Nasopharyngitis—Docetaxel—melanoma	0.000549	0.00146	CcSEcCtD
Maraviroc—Alanine aminotransferase increased—Docetaxel—melanoma	0.000542	0.00144	CcSEcCtD
Maraviroc—Tremor—Carmustine—melanoma	0.000539	0.00143	CcSEcCtD
Maraviroc—Oedema—Bleomycin—melanoma	0.000538	0.00143	CcSEcCtD
Maraviroc—Infection—Bleomycin—melanoma	0.000534	0.00142	CcSEcCtD
Maraviroc—Anaemia—Carmustine—melanoma	0.000532	0.00141	CcSEcCtD
Maraviroc—Nausea—Vemurafenib—melanoma	0.000527	0.0014	CcSEcCtD
Maraviroc—Myalgia—Dactinomycin—melanoma	0.000523	0.00139	CcSEcCtD
Maraviroc—Bronchospasm—Docetaxel—melanoma	0.000522	0.00139	CcSEcCtD
Maraviroc—Tremor—Temozolomide—melanoma	0.000521	0.00138	CcSEcCtD
Maraviroc—Discomfort—Dactinomycin—melanoma	0.000517	0.00137	CcSEcCtD
Maraviroc—Angina pectoris—Docetaxel—melanoma	0.000517	0.00137	CcSEcCtD
Maraviroc—Leukopenia—Carmustine—melanoma	0.000515	0.00137	CcSEcCtD
Maraviroc—Anaemia—Temozolomide—melanoma	0.000514	0.00137	CcSEcCtD
Maraviroc—Anorexia—Bleomycin—melanoma	0.000513	0.00136	CcSEcCtD
Maraviroc—Pancytopenia—Docetaxel—melanoma	0.000504	0.00134	CcSEcCtD
Maraviroc—Oedema—Dactinomycin—melanoma	0.000502	0.00133	CcSEcCtD
Maraviroc—Convulsion—Carmustine—melanoma	0.000499	0.00132	CcSEcCtD
Maraviroc—Infection—Dactinomycin—melanoma	0.000498	0.00132	CcSEcCtD
Maraviroc—Leukopenia—Temozolomide—melanoma	0.000498	0.00132	CcSEcCtD
Maraviroc—Neutropenia—Docetaxel—melanoma	0.000496	0.00132	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Bleomycin—melanoma	0.00049	0.0013	CcSEcCtD
Maraviroc—Myalgia—Carmustine—melanoma	0.00049	0.0013	CcSEcCtD
Maraviroc—Anxiety—Carmustine—melanoma	0.000488	0.0013	CcSEcCtD
Maraviroc—Cough—Temozolomide—melanoma	0.000485	0.00129	CcSEcCtD
Maraviroc—Paraesthesia—Bleomycin—melanoma	0.000483	0.00128	CcSEcCtD
Maraviroc—Convulsion—Temozolomide—melanoma	0.000482	0.00128	CcSEcCtD
Maraviroc—Anorexia—Dactinomycin—melanoma	0.000478	0.00127	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—PLCB4—melanoma	0.000476	0.00148	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL1—melanoma	0.000476	0.00148	CbGpPWpGaD
Maraviroc—Pneumonia—Docetaxel—melanoma	0.000476	0.00126	CcSEcCtD
Maraviroc—Myalgia—Temozolomide—melanoma	0.000473	0.00126	CcSEcCtD
Maraviroc—Infestation NOS—Docetaxel—melanoma	0.000473	0.00126	CcSEcCtD
Maraviroc—Infestation—Docetaxel—melanoma	0.000473	0.00126	CcSEcCtD
Maraviroc—Anxiety—Temozolomide—melanoma	0.000472	0.00125	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00047	0.00125	CcSEcCtD
Maraviroc—Oedema—Carmustine—melanoma	0.00047	0.00125	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000469	0.00125	CcSEcCtD
Maraviroc—Discomfort—Temozolomide—melanoma	0.000468	0.00124	CcSEcCtD
Maraviroc—Decreased appetite—Bleomycin—melanoma	0.000468	0.00124	CcSEcCtD
Maraviroc—Infection—Carmustine—melanoma	0.000466	0.00124	CcSEcCtD
Maraviroc—Acute coronary syndrome—Docetaxel—melanoma	0.000466	0.00124	CcSEcCtD
Maraviroc—Renal failure—Docetaxel—melanoma	0.000465	0.00124	CcSEcCtD
Maraviroc—Myocardial infarction—Docetaxel—melanoma	0.000464	0.00123	CcSEcCtD
Maraviroc—Neuropathy peripheral—Docetaxel—melanoma	0.000464	0.00123	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCR2—melanoma	0.000463	0.00144	CbGpPWpGaD
Maraviroc—Jaundice—Docetaxel—melanoma	0.000461	0.00123	CcSEcCtD
Maraviroc—Stomatitis—Docetaxel—melanoma	0.000461	0.00123	CcSEcCtD
Maraviroc—Pain—Bleomycin—melanoma	0.00046	0.00122	CcSEcCtD
Maraviroc—Conjunctivitis—Docetaxel—melanoma	0.00046	0.00122	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000457	0.00121	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—RAC2—melanoma	0.000456	0.00141	CbGpPWpGaD
Maraviroc—Oedema—Temozolomide—melanoma	0.000454	0.00121	CcSEcCtD
Maraviroc—CCR5—G alpha (i) signalling events—CXCL8—melanoma	0.000452	0.0014	CbGpPWpGaD
Maraviroc—Infection—Temozolomide—melanoma	0.000451	0.0012	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—WNT5A—melanoma	0.000449	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TRRAP—melanoma	0.000448	0.00139	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CUL3—melanoma	0.000448	0.00139	CbGpPWpGaD
Maraviroc—Anorexia—Carmustine—melanoma	0.000448	0.00119	CcSEcCtD
Maraviroc—Hepatobiliary disease—Docetaxel—melanoma	0.000447	0.00119	CcSEcCtD
Maraviroc—Nervous system disorder—Temozolomide—melanoma	0.000445	0.00118	CcSEcCtD
Maraviroc—Agranulocytosis—Docetaxel—melanoma	0.000442	0.00117	CcSEcCtD
Maraviroc—Skin disorder—Temozolomide—melanoma	0.000441	0.00117	CcSEcCtD
Maraviroc—CYP3A4—Irinotecan Pathway—APC—melanoma	0.000437	0.00135	CbGpPWpGaD
Maraviroc—Decreased appetite—Dactinomycin—melanoma	0.000436	0.00116	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—AKR1B10—melanoma	0.000436	0.00135	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—F2R—melanoma	0.000434	0.00135	CbGpPWpGaD
Maraviroc—Fatigue—Dactinomycin—melanoma	0.000433	0.00115	CcSEcCtD
Maraviroc—Anorexia—Temozolomide—melanoma	0.000433	0.00115	CcSEcCtD
Maraviroc—Pain—Dactinomycin—melanoma	0.000429	0.00114	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Carmustine—melanoma	0.000428	0.00114	CcSEcCtD
Maraviroc—Rhinitis—Docetaxel—melanoma	0.000426	0.00113	CcSEcCtD
Maraviroc—Body temperature increased—Bleomycin—melanoma	0.000425	0.00113	CcSEcCtD
Maraviroc—Insomnia—Carmustine—melanoma	0.000425	0.00113	CcSEcCtD
Maraviroc—Paraesthesia—Carmustine—melanoma	0.000422	0.00112	CcSEcCtD
Maraviroc—Pharyngitis—Docetaxel—melanoma	0.000422	0.00112	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—EDNRB—melanoma	0.00042	0.0013	CbGpPWpGaD
Maraviroc—Urinary tract disorder—Docetaxel—melanoma	0.000419	0.00111	CcSEcCtD
Maraviroc—Connective tissue disorder—Docetaxel—melanoma	0.000417	0.00111	CcSEcCtD
Maraviroc—Urethral disorder—Docetaxel—melanoma	0.000416	0.00111	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Temozolomide—melanoma	0.000413	0.0011	CcSEcCtD
Maraviroc—CCR5—Disease—HDAC6—melanoma	0.000412	0.00128	CbGpPWpGaD
Maraviroc—Insomnia—Temozolomide—melanoma	0.00041	0.00109	CcSEcCtD
Maraviroc—Gastrointestinal pain—Dactinomycin—melanoma	0.00041	0.00109	CcSEcCtD
Maraviroc—Decreased appetite—Carmustine—melanoma	0.000408	0.00108	CcSEcCtD
Maraviroc—Paraesthesia—Temozolomide—melanoma	0.000407	0.00108	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Carmustine—melanoma	0.000405	0.00108	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—F2RL1—melanoma	0.000405	0.00126	CbGpPWpGaD
Maraviroc—Erythema multiforme—Docetaxel—melanoma	0.000402	0.00107	CcSEcCtD
Maraviroc—Pain—Carmustine—melanoma	0.000402	0.00107	CcSEcCtD
Maraviroc—Constipation—Carmustine—melanoma	0.000402	0.00107	CcSEcCtD
Maraviroc—Eye disorder—Docetaxel—melanoma	0.000397	0.00105	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—GNA11—melanoma	0.000397	0.00123	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—GAB2—melanoma	0.000397	0.00123	CbGpPWpGaD
Maraviroc—Abdominal pain—Dactinomycin—melanoma	0.000397	0.00105	CcSEcCtD
Maraviroc—Body temperature increased—Dactinomycin—melanoma	0.000397	0.00105	CcSEcCtD
Maraviroc—Hypersensitivity—Bleomycin—melanoma	0.000396	0.00105	CcSEcCtD
Maraviroc—Decreased appetite—Temozolomide—melanoma	0.000394	0.00105	CcSEcCtD
Maraviroc—Cardiac disorder—Docetaxel—melanoma	0.000394	0.00105	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—F2R—melanoma	0.000394	0.00122	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Temozolomide—melanoma	0.000392	0.00104	CcSEcCtD
Maraviroc—Fatigue—Temozolomide—melanoma	0.000391	0.00104	CcSEcCtD
Maraviroc—CCR5—Disease—NPPA—melanoma	0.000391	0.00121	CbGpPWpGaD
Maraviroc—Constipation—Temozolomide—melanoma	0.000388	0.00103	CcSEcCtD
Maraviroc—Pain—Temozolomide—melanoma	0.000388	0.00103	CcSEcCtD
Maraviroc—Asthenia—Bleomycin—melanoma	0.000386	0.00103	CcSEcCtD
Maraviroc—Angiopathy—Docetaxel—melanoma	0.000385	0.00102	CcSEcCtD
Maraviroc—Gastrointestinal pain—Carmustine—melanoma	0.000384	0.00102	CcSEcCtD
Maraviroc—Mediastinal disorder—Docetaxel—melanoma	0.000383	0.00102	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EDNRB—melanoma	0.000381	0.00118	CbGpPWpGaD
Maraviroc—CCR5—Disease—VCAN—melanoma	0.000381	0.00118	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GRM3—melanoma	0.000381	0.00118	CbGpPWpGaD
Maraviroc—Pruritus—Bleomycin—melanoma	0.000381	0.00101	CcSEcCtD
Maraviroc—CCR5—Disease—WNT5A—melanoma	0.000378	0.00117	CbGpPWpGaD
Maraviroc—Alopecia—Docetaxel—melanoma	0.000375	0.000997	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—CXCR4—melanoma	0.000373	0.00116	CbGpPWpGaD
Maraviroc—Mental disorder—Docetaxel—melanoma	0.000372	0.000989	CcSEcCtD
Maraviroc—Abdominal pain—Carmustine—melanoma	0.000371	0.000986	CcSEcCtD
Maraviroc—Body temperature increased—Carmustine—melanoma	0.000371	0.000986	CcSEcCtD
Maraviroc—Gastrointestinal pain—Temozolomide—melanoma	0.000371	0.000986	CcSEcCtD
Maraviroc—Malnutrition—Docetaxel—melanoma	0.00037	0.000983	CcSEcCtD
Maraviroc—Erythema—Docetaxel—melanoma	0.00037	0.000983	CcSEcCtD
Maraviroc—Hypersensitivity—Dactinomycin—melanoma	0.00037	0.000982	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—GNAQ—melanoma	0.000369	0.00114	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KISS1—melanoma	0.000361	0.00112	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GAB2—melanoma	0.00036	0.00112	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—GNA11—melanoma	0.00036	0.00112	CbGpPWpGaD
Maraviroc—Asthenia—Dactinomycin—melanoma	0.00036	0.000957	CcSEcCtD
Maraviroc—CCR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	0.000359	0.00111	CbGpPWpGaD
Maraviroc—Abdominal pain—Temozolomide—melanoma	0.000359	0.000953	CcSEcCtD
Maraviroc—Body temperature increased—Temozolomide—melanoma	0.000359	0.000953	CcSEcCtD
Maraviroc—CYP3A4—Biological oxidations—UGT2B10—melanoma	0.000352	0.00109	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SKI—melanoma	0.00035	0.00108	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCR1—melanoma	0.00035	0.00108	CbGpPWpGaD
Maraviroc—Hypersensitivity—Carmustine—melanoma	0.000346	0.000919	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—MC1R—melanoma	0.000344	0.00107	CbGpPWpGaD
Maraviroc—Diarrhoea—Dactinomycin—melanoma	0.000343	0.000912	CcSEcCtD
Maraviroc—Vomiting—Bleomycin—melanoma	0.000342	0.000909	CcSEcCtD
Maraviroc—Anaemia—Docetaxel—melanoma	0.000342	0.000908	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—AKT3—melanoma	0.00034	0.00106	CbGpPWpGaD
Maraviroc—Rash—Bleomycin—melanoma	0.000339	0.000901	CcSEcCtD
Maraviroc—Dermatitis—Bleomycin—melanoma	0.000339	0.000901	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CXCR4—melanoma	0.000339	0.00105	CbGpPWpGaD
Maraviroc—Asthenia—Carmustine—melanoma	0.000337	0.000895	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—GNAQ—melanoma	0.000335	0.00104	CbGpPWpGaD
Maraviroc—Hypersensitivity—Temozolomide—melanoma	0.000334	0.000888	CcSEcCtD
Maraviroc—Syncope—Docetaxel—melanoma	0.000332	0.000881	CcSEcCtD
Maraviroc—Leukopenia—Docetaxel—melanoma	0.000331	0.00088	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GRM1—melanoma	0.00033	0.00102	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCR7—melanoma	0.00033	0.00102	CbGpPWpGaD
Maraviroc—Asthenia—Temozolomide—melanoma	0.000326	0.000865	CcSEcCtD
Maraviroc—Loss of consciousness—Docetaxel—melanoma	0.000325	0.000864	CcSEcCtD
Maraviroc—Cough—Docetaxel—melanoma	0.000323	0.000857	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SUFU—melanoma	0.000322	0.000998	CbGpPWpGaD
Maraviroc—Diarrhoea—Carmustine—melanoma	0.000321	0.000854	CcSEcCtD
Maraviroc—Pruritus—Temozolomide—melanoma	0.000321	0.000853	CcSEcCtD
Maraviroc—Convulsion—Docetaxel—melanoma	0.00032	0.000851	CcSEcCtD
Maraviroc—Nausea—Bleomycin—melanoma	0.00032	0.000849	CcSEcCtD
Maraviroc—Vomiting—Dactinomycin—melanoma	0.000319	0.000848	CcSEcCtD
Maraviroc—Rash—Dactinomycin—melanoma	0.000316	0.000841	CcSEcCtD
Maraviroc—Myalgia—Docetaxel—melanoma	0.000315	0.000837	CcSEcCtD
Maraviroc—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	0.000313	0.00097	CbGpPWpGaD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000313	0.000831	CcSEcCtD
Maraviroc—Dizziness—Carmustine—melanoma	0.000311	0.000825	CcSEcCtD
Maraviroc—Diarrhoea—Temozolomide—melanoma	0.00031	0.000825	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—AKT3—melanoma	0.000309	0.000959	CbGpPWpGaD
Maraviroc—CCR5—Disease—GAB2—melanoma	0.000304	0.000943	CbGpPWpGaD
Maraviroc—Oedema—Docetaxel—melanoma	0.000302	0.000802	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RHOB—melanoma	0.0003	0.000932	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BCL2L11—melanoma	0.0003	0.000932	CbGpPWpGaD
Maraviroc—Dizziness—Temozolomide—melanoma	0.0003	0.000797	CcSEcCtD
Maraviroc—Infection—Docetaxel—melanoma	0.0003	0.000797	CcSEcCtD
Maraviroc—Vomiting—Carmustine—melanoma	0.000299	0.000793	CcSEcCtD
Maraviroc—Nausea—Dactinomycin—melanoma	0.000298	0.000792	CcSEcCtD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—melanoma	0.000298	0.000924	CbGpPWpGaD
Maraviroc—CCR5—Disease—FASN—melanoma	0.000297	0.000923	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	0.000297	0.000922	CbGpPWpGaD
Maraviroc—Shock—Docetaxel—melanoma	0.000297	0.000789	CcSEcCtD
Maraviroc—Rash—Carmustine—melanoma	0.000296	0.000787	CcSEcCtD
Maraviroc—Nervous system disorder—Docetaxel—melanoma	0.000296	0.000786	CcSEcCtD
Maraviroc—Dermatitis—Carmustine—melanoma	0.000296	0.000786	CcSEcCtD
Maraviroc—Headache—Carmustine—melanoma	0.000294	0.000782	CcSEcCtD
Maraviroc—Skin disorder—Docetaxel—melanoma	0.000293	0.000779	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—HDAC6—melanoma	0.000289	0.000896	CbGpPWpGaD
Maraviroc—Vomiting—Temozolomide—melanoma	0.000289	0.000767	CcSEcCtD
Maraviroc—Anorexia—Docetaxel—melanoma	0.000288	0.000764	CcSEcCtD
Maraviroc—Rash—Temozolomide—melanoma	0.000286	0.00076	CcSEcCtD
Maraviroc—CCR5—GPCR downstream signaling—EDN1—melanoma	0.000286	0.000887	CbGpPWpGaD
Maraviroc—Dermatitis—Temozolomide—melanoma	0.000286	0.00076	CcSEcCtD
Maraviroc—CCR5—Disease—FOXO4—melanoma	0.000286	0.000886	CbGpPWpGaD
Maraviroc—CCR5—Disease—CXCR4—melanoma	0.000286	0.000886	CbGpPWpGaD
Maraviroc—CCR5—Disease—HDAC2—melanoma	0.000286	0.000886	CbGpPWpGaD
Maraviroc—Headache—Temozolomide—melanoma	0.000284	0.000755	CcSEcCtD
Maraviroc—CYP3A4—Tryptophan metabolism—CYP1B1—melanoma	0.000284	0.000881	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD44—melanoma	0.000283	0.000877	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CSF2—melanoma	0.00028	0.000867	CbGpPWpGaD
Maraviroc—Nausea—Carmustine—melanoma	0.000279	0.000741	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Docetaxel—melanoma	0.000275	0.000731	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—CXCR2—melanoma	0.000274	0.000849	CbGpPWpGaD
Maraviroc—CCR5—GPCR ligand binding—CXCL8—melanoma	0.000274	0.000848	CbGpPWpGaD
Maraviroc—Insomnia—Docetaxel—melanoma	0.000273	0.000725	CcSEcCtD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	0.000273	0.000846	CbGpPWpGaD
Maraviroc—Paraesthesia—Docetaxel—melanoma	0.000271	0.00072	CcSEcCtD
Maraviroc—Nausea—Temozolomide—melanoma	0.00027	0.000716	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—RAC2—melanoma	0.000269	0.000835	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—melanoma	0.000269	0.000835	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PRKCA—melanoma	0.000268	0.000831	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—WNT5A—melanoma	0.000265	0.000822	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFC—melanoma	0.000265	0.000822	CbGpPWpGaD
Maraviroc—Decreased appetite—Docetaxel—melanoma	0.000262	0.000697	CcSEcCtD
Maraviroc—CCR5—Disease—AKT3—melanoma	0.000261	0.000809	CbGpPWpGaD
Maraviroc—Gastrointestinal disorder—Docetaxel—melanoma	0.000261	0.000692	CcSEcCtD
Maraviroc—Fatigue—Docetaxel—melanoma	0.00026	0.000691	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—EDN1—melanoma	0.00026	0.000806	CbGpPWpGaD
Maraviroc—Constipation—Docetaxel—melanoma	0.000258	0.000686	CcSEcCtD
Maraviroc—Pain—Docetaxel—melanoma	0.000258	0.000686	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—CSF2—melanoma	0.000254	0.000787	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—RAC1—melanoma	0.000248	0.000771	CbGpPWpGaD
Maraviroc—Gastrointestinal pain—Docetaxel—melanoma	0.000247	0.000656	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—PRKCA—melanoma	0.000243	0.000755	CbGpPWpGaD
Maraviroc—Body temperature increased—Docetaxel—melanoma	0.000239	0.000634	CcSEcCtD
Maraviroc—Abdominal pain—Docetaxel—melanoma	0.000239	0.000634	CcSEcCtD
Maraviroc—CCR5—Signaling by GPCR—MAP2K2—melanoma	0.000238	0.000738	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—F2R—melanoma	0.000233	0.000722	CbGpPWpGaD
Maraviroc—CCR5—Disease—ERBB4—melanoma	0.00023	0.000715	CbGpPWpGaD
Maraviroc—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	0.00023	0.000712	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN2B—melanoma	0.000228	0.000708	CbGpPWpGaD
Maraviroc—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—melanoma	0.000227	0.000703	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—RAC1—melanoma	0.000226	0.0007	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EDNRB—melanoma	0.000225	0.000699	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—AKR1B10—melanoma	0.000224	0.000695	CbGpPWpGaD
Maraviroc—Hypersensitivity—Docetaxel—melanoma	0.000222	0.000591	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	0.000221	0.000686	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD86—melanoma	0.000221	0.000685	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTK2B—melanoma	0.000219	0.000679	CbGpPWpGaD
Maraviroc—Asthenia—Docetaxel—melanoma	0.000217	0.000575	CcSEcCtD
Maraviroc—CCR5—Disease—FGF1—melanoma	0.000214	0.000664	CbGpPWpGaD
Maraviroc—Pruritus—Docetaxel—melanoma	0.000214	0.000567	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GNA11—melanoma	0.000213	0.00066	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—GAB2—melanoma	0.000213	0.00066	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FLT1—melanoma	0.000212	0.000657	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CG—melanoma	0.00021	0.000651	CbGpPWpGaD
Maraviroc—CCR5—Disease—PDGFRA—melanoma	0.000207	0.000643	CbGpPWpGaD
Maraviroc—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	0.000207	0.000643	CbGpPWpGaD
Maraviroc—Diarrhoea—Docetaxel—melanoma	0.000206	0.000549	CcSEcCtD
Maraviroc—CCR5—Disease—PRKCA—melanoma	0.000205	0.000637	CbGpPWpGaD
Maraviroc—CCR5—Disease—ERCC2—melanoma	0.000204	0.000632	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAP2K2—melanoma	0.000201	0.000623	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCR4—melanoma	0.0002	0.000621	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FOXO4—melanoma	0.0002	0.000621	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HDAC2—melanoma	0.0002	0.000621	CbGpPWpGaD
Maraviroc—Dizziness—Docetaxel—melanoma	0.0002	0.00053	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—GNAQ—melanoma	0.000198	0.000614	CbGpPWpGaD
Maraviroc—Vomiting—Docetaxel—melanoma	0.000192	0.00051	CcSEcCtD
Maraviroc—CCR5—Disease—TERT—melanoma	0.000191	0.000592	CbGpPWpGaD
Maraviroc—CCR5—Disease—HLA-A—melanoma	0.000191	0.000592	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CG—melanoma	0.000191	0.000591	CbGpPWpGaD
Maraviroc—CCR5—Disease—RAC1—melanoma	0.00019	0.00059	CbGpPWpGaD
Maraviroc—Rash—Docetaxel—melanoma	0.00019	0.000506	CcSEcCtD
Maraviroc—Dermatitis—Docetaxel—melanoma	0.00019	0.000505	CcSEcCtD
Maraviroc—Headache—Docetaxel—melanoma	0.000189	0.000502	CcSEcCtD
Maraviroc—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	0.000186	0.000577	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SYK—melanoma	0.000186	0.000577	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CD—melanoma	0.000185	0.000572	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NGFR—melanoma	0.000183	0.000566	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ITGAV—melanoma	0.000183	0.000566	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT3—melanoma	0.000183	0.000566	CbGpPWpGaD
Maraviroc—CCR5—Disease—HIF1A—melanoma	0.000183	0.000566	CbGpPWpGaD
Maraviroc—Nausea—Docetaxel—melanoma	0.000179	0.000476	CcSEcCtD
Maraviroc—CCR5—Signaling Pathways—SOCS1—melanoma	0.000169	0.000525	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAP2K1—melanoma	0.000169	0.000523	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—S100B—melanoma	0.000169	0.000523	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CD—melanoma	0.000168	0.00052	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOS2—melanoma	0.000166	0.000515	CbGpPWpGaD
Maraviroc—CCR5—Disease—NOTCH1—melanoma	0.000164	0.00051	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB4—melanoma	0.000161	0.0005	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD80—melanoma	0.000161	0.0005	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CB—melanoma	0.000161	0.000499	CbGpPWpGaD
Maraviroc—CCR5—Disease—KIT—melanoma	0.000161	0.000499	CbGpPWpGaD
Maraviroc—CCR5—Disease—APC—melanoma	0.000161	0.000499	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN2B—melanoma	0.00016	0.000496	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGF—melanoma	0.000159	0.000493	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CD86—melanoma	0.000155	0.00048	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—CXCL8—melanoma	0.000155	0.00048	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EDN1—melanoma	0.000153	0.000476	CbGpPWpGaD
Maraviroc—CCR5—Disease—BRAF—melanoma	0.000151	0.000469	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CSF2—melanoma	0.00015	0.000465	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF1—melanoma	0.00015	0.000465	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—IL2—melanoma	0.000148	0.000458	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—E2F1—melanoma	0.000147	0.000455	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CB—melanoma	0.000146	0.000453	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PDGFRA—melanoma	0.000145	0.000451	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PRKCA—melanoma	0.000144	0.000446	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ITGB3—melanoma	0.000144	0.000446	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAP2K1—melanoma	0.000142	0.000441	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CD—melanoma	0.000141	0.000439	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—SPP1—melanoma	0.000141	0.000437	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAP2K2—melanoma	0.000141	0.000436	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—CXCL8—melanoma	0.00014	0.000435	CbGpPWpGaD
Maraviroc—CCR5—Disease—FGF2—melanoma	0.000135	0.00042	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL2—melanoma	0.000134	0.000416	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TERT—melanoma	0.000134	0.000415	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—RAC1—melanoma	0.000133	0.000413	CbGpPWpGaD
Maraviroc—CYP3A4—Tryptophan metabolism—MDM2—melanoma	0.000133	0.000412	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HIF1A—melanoma	0.000128	0.000397	CbGpPWpGaD
Maraviroc—CCR5—Disease—MDM2—melanoma	0.000127	0.000393	CbGpPWpGaD
Maraviroc—CCR5—Disease—ERBB2—melanoma	0.000125	0.000387	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CB—melanoma	0.000123	0.000382	CbGpPWpGaD
Maraviroc—CCR5—Disease—CD4—melanoma	0.000123	0.000382	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KDR—melanoma	0.000122	0.000379	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTGS2—melanoma	0.000122	0.000379	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FN1—melanoma	0.000118	0.000365	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP17A1—melanoma	0.000117	0.000364	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP17A1—melanoma	0.000116	0.000359	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1B—melanoma	0.000116	0.000359	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NOTCH1—melanoma	0.000115	0.000357	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CD80—melanoma	0.000113	0.00035	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KIT—melanoma	0.000113	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—APC—melanoma	0.000113	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CG—melanoma	0.000113	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—NRAS—melanoma	0.000113	0.000349	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGF—melanoma	0.000111	0.000345	CbGpPWpGaD
Maraviroc—CCR5—Disease—CTNNB1—melanoma	0.000109	0.000339	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAPK3—melanoma	0.000108	0.000335	CbGpPWpGaD
Maraviroc—CCR5—Disease—CDKN1A—melanoma	0.000107	0.000331	CbGpPWpGaD
Maraviroc—CCR5—Disease—PTEN—melanoma	0.000106	0.00033	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—BRAF—melanoma	0.000106	0.000328	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IGF1—melanoma	0.000103	0.00032	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—MAPK1—melanoma	0.000103	0.000318	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—EGFR—melanoma	0.000103	0.000318	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAP2K1—melanoma	9.96e-05	0.000309	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CD—melanoma	9.9e-05	0.000307	CbGpPWpGaD
Maraviroc—CYP3A4—Biological oxidations—CYP1B1—melanoma	9.89e-05	0.000307	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—PIK3CA—melanoma	9.8e-05	0.000304	CbGpPWpGaD
Maraviroc—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	9.75e-05	0.000303	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—KRAS—melanoma	9.69e-05	0.000301	CbGpPWpGaD
Maraviroc—CCR5—Disease—STAT3—melanoma	9.52e-05	0.000295	CbGpPWpGaD
Maraviroc—CCR5—Disease—NRAS—melanoma	9.5e-05	0.000295	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—FGF2—melanoma	9.48e-05	0.000294	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK3—melanoma	9.1e-05	0.000282	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—PIK3CA—melanoma	8.9e-05	0.000276	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MDM2—melanoma	8.87e-05	0.000275	CbGpPWpGaD
Maraviroc—CCR5—Disease—MYC—melanoma	8.85e-05	0.000274	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—ERBB2—melanoma	8.74e-05	0.000271	CbGpPWpGaD
Maraviroc—CCR5—Disease—MAPK1—melanoma	8.66e-05	0.000269	CbGpPWpGaD
Maraviroc—CCR5—Disease—EGFR—melanoma	8.65e-05	0.000268	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CB—melanoma	8.63e-05	0.000268	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CXCL8—melanoma	8.29e-05	0.000257	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—HRAS—melanoma	8.24e-05	0.000256	CbGpPWpGaD
Maraviroc—CCR5—Disease—KRAS—melanoma	8.18e-05	0.000254	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1B—melanoma	8.1e-05	0.000251	CbGpPWpGaD
Maraviroc—CCR5—GPCR downstream signaling—AKT1—melanoma	8.01e-05	0.000248	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CASP3—melanoma	7.94e-05	0.000246	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL2—melanoma	7.92e-05	0.000246	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—IL6—melanoma	7.88e-05	0.000245	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CCND1—melanoma	7.72e-05	0.00024	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CTNNB1—melanoma	7.65e-05	0.000237	CbGpPWpGaD
Maraviroc—CCR5—Disease—PIK3CA—melanoma	7.51e-05	0.000233	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MMP9—melanoma	7.5e-05	0.000233	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—CDKN1A—melanoma	7.47e-05	0.000232	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PTEN—melanoma	7.46e-05	0.000231	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NFKB1—melanoma	7.42e-05	0.00023	CbGpPWpGaD
Maraviroc—CCR5—Signaling by GPCR—AKT1—melanoma	7.27e-05	0.000226	CbGpPWpGaD
Maraviroc—CCR5—Disease—HRAS—melanoma	6.95e-05	0.000216	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—VEGFA—melanoma	6.73e-05	0.000209	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—STAT3—melanoma	6.67e-05	0.000207	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—NRAS—melanoma	6.65e-05	0.000206	CbGpPWpGaD
Maraviroc—CCR5—Disease—IL6—melanoma	6.65e-05	0.000206	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ACER3—melanoma	6.59e-05	0.000204	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK3—melanoma	6.37e-05	0.000198	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MYC—melanoma	6.2e-05	0.000192	CbGpPWpGaD
Maraviroc—CCR5—Disease—AKT1—melanoma	6.14e-05	0.00019	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—MAPK1—melanoma	6.06e-05	0.000188	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—EGFR—melanoma	6.06e-05	0.000188	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—UGT2B10—melanoma	6.03e-05	0.000187	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—KRAS—melanoma	5.73e-05	0.000178	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HS3ST5—melanoma	5.6e-05	0.000174	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—PIK3CA—melanoma	5.26e-05	0.000163	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—TP53—melanoma	5.09e-05	0.000158	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—HRAS—melanoma	4.87e-05	0.000151	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—IL6—melanoma	4.66e-05	0.000144	CbGpPWpGaD
Maraviroc—CCR5—Signaling Pathways—AKT1—melanoma	4.3e-05	0.000133	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLCB4—melanoma	4.25e-05	0.000132	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIP4K2A—melanoma	3.99e-05	0.000124	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC6A11—melanoma	3.99e-05	0.000124	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—MTAP—melanoma	3.88e-05	0.000121	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PHGDH—melanoma	3.46e-05	0.000107	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—LUM—melanoma	3.46e-05	0.000107	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—HPSE—melanoma	3.4e-05	0.000105	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CUBN—melanoma	3.33e-05	0.000103	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CSPG4—melanoma	3.22e-05	9.99e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SDHD—melanoma	3.22e-05	9.99e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—BSG—melanoma	3.22e-05	9.99e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GPAM—melanoma	3.12e-05	9.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PLA2G6—melanoma	2.65e-05	8.22e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—VCAN—melanoma	2.38e-05	7.39e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP17A1—melanoma	2.01e-05	6.23e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GNA11—melanoma	1.9e-05	5.89e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—FASN—melanoma	1.86e-05	5.76e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—SLC5A5—melanoma	1.83e-05	5.67e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—GNAQ—melanoma	1.76e-05	5.47e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CD44—melanoma	1.76e-05	5.47e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—CYP1B1—melanoma	1.69e-05	5.25e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ABCB1—melanoma	1.39e-05	4.32e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PRKCA—melanoma	1.28e-05	3.98e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ERCC2—melanoma	1.27e-05	3.94e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CG—melanoma	1e-05	3.11e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PPARG—melanoma	9.69e-06	3.01e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CD—melanoma	8.82e-06	2.74e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—ALB—melanoma	8.71e-06	2.7e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CB—melanoma	7.69e-06	2.39e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTGS2—melanoma	7.62e-06	2.36e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PTEN—melanoma	6.65e-06	2.06e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—PIK3CA—melanoma	4.69e-06	1.45e-05	CbGpPWpGaD
Maraviroc—CYP3A4—Metabolism—AKT1—melanoma	3.83e-06	1.19e-05	CbGpPWpGaD
